Cargando…
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review
Reports of immune-related adverse events caused by programmed cell death-ligand 1 (PD-L1) inhibitor have been emerging. Herein, we report a subacute cutaneous lupus erythematosus (SCLE)-like eruption presented after the treatment of durvalumab in a patient with extensive-stage small cell lung carcin...
Autores principales: | Pratumchart, Nathathai, Chanprapaph, Kumutnart, Topibulpong, Nuttapong, Tankunakorn, Jutamas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763206/ https://www.ncbi.nlm.nih.gov/pubmed/35046689 http://dx.doi.org/10.2147/CCID.S344445 |
Ejemplares similares
-
Dermatologic Manifestations, Histologic Features and Disease Progression among Cutaneous Lupus Erythematosus Subtypes: A Prospective Observational Study in Asians
por: Chanprapaph, Kumutnart, et al.
Publicado: (2020) -
Vesiculobullous diseases in relation to lupus erythematosus
por: Rutnin, Suthinee, et al.
Publicado: (2019) -
Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
por: Kanokrungsee, Silada, et al.
Publicado: (2021) -
Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review
por: Ratanapokasatit, Yanisa, et al.
Publicado: (2023) -
Scleroderma-Like Lupus Panniculitis: A Case Report and Literature Review
por: Pinyowiwat, Prinpat, et al.
Publicado: (2023)